Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma
Rapa Therapeutics LLC
Rapa Therapeutics LLC
National Institutes of Health Clinical Center (CC)
Biocon Limited
Duke University
Bristol-Myers Squibb
Peking University Cancer Hospital & Institute
M.D. Anderson Cancer Center
University Hospital, Grenoble
Kaiser Permanente
OHSU Knight Cancer Institute
Qingdao Sino-Cell Biomedicine Co., Ltd.
Indiana University
Nantes University Hospital
Institute of Health Information and Statistics of the Czech Republic
Second Life Therapeutics
Onchilles Pharma Inc
UNICANCER
McMaster University
Ohio State University Comprehensive Cancer Center
The Christie NHS Foundation Trust
AccSalus Biosciences, Inc.
OncoHost Ltd.
Petrov, Andrey
Eastern Cooperative Oncology Group
Hangzhou DAC Biotechnology Co., Ltd.
Vastra Gotaland Region
Xijing Hospital
SRH Wald-Klinikum Gera GmbH
Eastern Cooperative Oncology Group
Oncodesign Precision Medicine
Xynomic Pharmaceuticals, Inc.
Rabin Medical Center
The University of Hong Kong-Shenzhen Hospital
Vastra Gotaland Region
Erasmus Medical Center
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Royal Marsden NHS Foundation Trust
M.D. Anderson Cancer Center
Henan Cancer Hospital
University of Auckland, New Zealand
European Institute of Oncology
Fudan University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Royal Marsden NHS Foundation Trust
The Christie NHS Foundation Trust
Herlev Hospital
Peking University Cancer Hospital & Institute
Hunan Cancer Hospital
Xijing Hospital
Power Life Sciences Inc.